Eupraxia Pharmaceuticals Inc
TSX:EPRX
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Price:
3.84 CAD
3.23%
Updated:
May 3, 2024
Eupraxia Pharmaceuticals Inc
Cash from Financing Activities
|
Eupraxia Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Cash from Financing Activities
CA$21m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is Eupraxia Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
21m
CAD
21m
CAD
Based on the financial report for Dec 31, 2023, Eupraxia Pharmaceuticals Inc's Cash from Financing Activities amounts to 21m CAD.
What is Eupraxia Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
32%
32%
Over the last year, the Cash from Financing Activities growth was 55%.
You don't have any saved screeners yet
